Finding – Page 4

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

2 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

2 months ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

2 months ago talkbio0Tagged Biological Markers, Clinical Development, Neuroinflammation, NLRP3 inhibitor, Parkinson 's disease, Phase 2a Trial, VENT-02, Ventus Therapeutics

Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers

Jazz Pharmaceuticals Appoints Dr. Ted Love to Board of Directors

2 months ago talkbio0Tagged Audit Committee, Board appointment, board of directors, Corporate governance, Jazz, Kenneth W. O’Keefe, Retirement, Science, Ted Love

Jazz Pharmaceuticals; Ted Love; Board appointment; Board of Directors; Corporate governance; Audit Committee; Science and Medicine Committee; Kenneth W. O’Keefe retirement

SheMed Secures Funding for UK Expansion

2 months ago talkbio0Tagged expansion, SheMed, UK, Weight Loss

SheMed; Weight Loss; UK Expansion; HealthTech

Eye Disease Biotech Kala Bio Collapses After Failed Clinical Trial, Lender Takes Control

2 months ago talkbio0Tagged Clinical trial failure, Corneal epithelial defect, Experimental drug, foreclosure proceedings, Kala Bio, KPI-012, lender takeover, Oxford Finance, PCED, Persistent, Shock, Workforce reduction

Kala Bio; biotech collapse; failed drug trial; KPI-012; persistent corneal epithelial defect; PCED; lender takeover; Oxford Finance; foreclosure proceedings; workforce reduction; clinical trial failure

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

2 months ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

2 months ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

2 months ago talkbio0Tagged AFFIRM-1, BNC210, Clinical Failure, Neuphoria, Phobia, Social, Post-Traumatic Stress Disorder, strategic review

Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD

Mixed Results for Roche’s Vamikibart in Phase III Uveitic Macular Edema Trials

2 months ago talkbio0Tagged central subfield, Clinical Relevance, MEERKAT trial, ocular adverse events, Phase 3 Clinical Trials, Roche (company), SANDCAT trial, Thick, uveitic macular edema, Vamikibart, vision improvement

Roche; vamikibart; uveitic macular edema; Phase III trials; MEERKAT trial; SANDCAT trial; vision improvement; central subfield thickness; clinical significance; ocular adverse events